- Home
- PSHG vs SYBX Comparison
PSHG vs SYBX Comparison
Compare PSHG & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- SYBX
- Stock Information
- Founded
- PSHG 2010
- SYBX N/A
- Country
- PSHG Greece
- SYBX United States
- Employees
- PSHG N/A
- SYBX N/A
- Industry
- PSHG Marine Transportation
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- SYBX Health Care
- Exchange
- PSHG Nasdaq
- SYBX Nasdaq
- Market Cap
- PSHG 20.3M
- SYBX 16.5M
- IPO Year
- PSHG N/A
- SYBX N/A
- Fundamental
- Price
- PSHG $1.64
- SYBX $1.36
- Analyst Decision
- PSHG Strong Buy
- SYBX Hold
- Analyst Count
- PSHG 1
- SYBX 1
- Target Price
- PSHG $6.50
- SYBX N/A
- AVG Volume (30 Days)
- PSHG 79.5K
- SYBX 18.8K
- Earning Date
- PSHG 02-20-2025
- SYBX 03-18-2025
- Dividend Yield
- PSHG N/A
- SYBX N/A
- EPS Growth
- PSHG N/A
- SYBX N/A
- EPS
- PSHG 1.51
- SYBX N/A
- Revenue
- PSHG $89,608,000.00
- SYBX $2,777,000.00
- Revenue This Year
- PSHG N/A
- SYBX N/A
- Revenue Next Year
- PSHG N/A
- SYBX N/A
- P/E Ratio
- PSHG $1.11
- SYBX N/A
- Revenue Growth
- PSHG N/A
- SYBX 292.23
- 52 Week Low
- PSHG $1.51
- SYBX $1.22
- 52 Week High
- PSHG $2.58
- SYBX $2.04
- Technical
- Relative Strength Index (RSI)
- PSHG 46.17
- SYBX 45.23
- Support Level
- PSHG $1.53
- SYBX $1.31
- Resistance Level
- PSHG $1.68
- SYBX $1.40
- Average True Range (ATR)
- PSHG 0.07
- SYBX 0.07
- MACD
- PSHG 0.01
- SYBX 0.00
- Stochastic Oscillator
- PSHG 65.79
- SYBX 60.61
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.